Abstract
Huntington’s disease (HD) is a hereditary neurodegenerative disorder, characterized by motor, psychiatric, and cognitive symptoms. The genetic defect responsible for the onset of the disease, expansion of CAG repeats in exon 1 of the gene that codes for huntingtin, has been unambiguously identified. The mechanisms by which the mutation causes the disease are not completely understood yet. However, defects in the energy metabolism of affected cells, which may cause oxidative damage, have been proposed as underlying molecular mechanisms that participate in the etiology of the disease. In this chapter, we describe biochemical methods that allow us to determine striatal oxidative damage in transgenic mice and in the quinolinic acid-induced excitotoxicity model in rat, and establish the status of protective cellular systems. The excitotoxic model is acute, easier and faster to perform than the transgenic model, and can within a short period provide valuable data to try new therapeutic strategies. The methods described in this chapter permit us to link the kynurenine pathway with the cascade of toxic and harmful reactions that cause the damage observed in HD. We consider that determining the mechanisms inducing oxidative damage in two different models of HD will allow the testing of drugs or other therapeutic strategies with antioxidant activities.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Browne SE, Bowling AC, MacGarvey U et al (1997) Oxidative damage and metabolic dysfunction in Huntington’s disease: selective vulnerability of the basal ganglia. Ann Neurol 41:646–653
Segovia J, Arregui L (2007) Mechanisms of neuronal death associated to Huntington’s disease. In: Massieu L, Arias C, Moran J (eds) The neurochemistry of neuronal death. Research Signpost, Trivandrum, p 197
Polidori MC, Mecocci P, Browne SE et al (1999) Oxidative damage to mitochondrial DNA in Huntington’s disease parietal cortex. Neurosci Lett 272:53–56
Arregui L, Segovia J (2004) Molecular strategies for the treatment of Huntington’s disease. Curr Pharmacogenomics 2:299–311
Arregui L, Segovia J (2009) Transgenic murine models for Huntington’s disease. In: Rocha-Arrieta LL, Granados-Soto V (eds) Models of neuropharmacology. Transworld Research Network, Trivandrum, p 35
Ross CA, Tabrizi SJ (2011) Huntington’s disease: from molecular pathogenesis to clinical treatment. Lancet Neurol 10:83–98
Beal MF, Kowall NW, Ellison DW et al (1986) Replication of the neurochemical characteristics of Huntington’s disease by quinolinic acid. Nature 321:168–171
Stone TW (1999) Neuropharmacology of quinolinic and kynurenic acids. Pharmacol Rev 45:309–379
Perez-Severiano F, Escalante B, Rios C (1998) Nitric oxide synthase inhibition prevents acute quinolinate-induced striatal neurotoxicity. Neurochem Res 23:1297–1302
Schwarcz R, Guidetti P, Sathyasaikumar KV et al (2010) Of mice, rats and men: revisiting the quinolinic acid hypothesis of Huntington’s disease. Prog Neurobiol 90:230–245
Sies H (1999) Glutathione and its role in cellular function. Free Radic Biol Med 27:916–921
Mangiarini L, Sathasivam K, Seller M et al (1996) Exon 1 of the HD gene with an expanded CAG repeat is sufficient to cause a progressive neurological phenotype in transgenic mice. Cell 87:493–506
Segovia J (2002) Transgenic model for the study of oxidative damage in Huntington’s disease. Methods Enzymol 353:365–373
Pérez-Severiano F, Ríos C, Segovia J (2000) Striatal oxidative damage parallels the expression of a neurological phenotype in mice transgenic for the mutation of Huntington’s disease. Brain Res 862:234–237
Paxinos G, Watson G (1984) The rat brain in stereotaxic coordinates. Academic, Sydney
Gutteridge JM, Halliwell B (1990) The measurement and mechanism of lipid peroxidation in biological systems. Trends Biochem Sci 15:129–135
Chan PH, Yurko M, Fishman RA (1982) Phospholipid degradation and cellular edema induced by free radicals in brain cortical slices. J Neurochem 38:525–531
Lowry OH, Rosebrougth NJ, Farr AL et al (1951) Protein measurement with the folin-phenol reagent. J Biol Chem 193:265–275
Perez-Severiano F, Santamaria A, Pedraza-Chaverri J et al (2004) Increased formation of reactive oxygen species, but no changes in glutathione peroxidase activity, in striata of mice transgenic for the Huntington’s disease mutation. Neurochem Res 29:729–733
Bindokas VP, Jordán J, Lee CC et al (1996) Superoxide production in rat hippocampal neurons: selective imaging with hydroethidine. J Neurosci 16:1324–1336
Zhao H, Joseph J, Fales HM et al (2005) Detection and characterization of the product of hydroethidine and intracellular superoxide by HPLC and limitations of fluorescence. Proc Natl Acad Sci USA 102:5727–5732
Arellano-Mendoza MG, Castillo-Henkel C, Medina-Santillan R et al (2008) Kidney damage after renal ablation is worsened in endothelial nitric oxide synthase (−/−) mice and improved by combined administration of L-arginine and antioxidants. Nephrology (Carlton) 13:218–227
Schuman EM, Madison DV (1994) Nitric oxide and synaptic function. Annu Rev Neurosci 17:153–183
Bredt DS, Snyder SH (1990) Isolation of nitric oxide synthetase, a calmodulin-requiring enzyme. Proc Natl Acad Sci USA 87:682–685
Pérez-Severiano F, Escalante B, Vergara P et al (2002) Age-dependent changes in nitric oxide synthase activity and protein expression in striata of mice transgenic for the Huntington’s Disease mutation. Brain Res 862:234–237
Díaz-Barriga F, Hernández JM, Carrizales L et al (1989) Interactions of cadmium with actin microfilaments. Toxicol In Vitro 3:277–284
Oberley LW, Spitz DR (1984) Assay of superoxide dismutase activity in tumor tissue. Methods Enzymol 105:457–464
Iqbal J, Whitney P (1991) Use of cyanide and diethyldithiocarbamate in the assay of superoxide dismutases. Free Radic Biol Med 10:69–77
Santamaría A, Pérez-Severiano F, Rodríguez-Martínez E et al (2001) Comparative analysis of superoxide dismutase activity between acute pharmacological models and a transgenic mouse model of Huntington’s disease. Neurochem Res 26:419–424
Bharath S, Hsu M, Kaur D et al (2002) Glutathione and Parkinson’s disease. Biochem Pharmacol 64:1037–1048
Hissing PJ, Hilf R (1976) A flourometric method for the determination of oxidized and reduced glutathione in tissues. Anal Biochem 74:214–226
Triggs WP, Willmore LJ (1984) In vivo lipid peroxidation in rat brain following intracortical Fe++ injection. J Neurochem 42:976–979
Acknowledgements
We want to thank Paula Vergara, Hilda Vargas and Perla D. Maldonado for their assistance and expertise in the development and use of several of the techniques described in this chapter. This work was partially supported by CONACyT grants 127357 (J.S.) and 61327 (F.P.S.).
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2013 Springer New York
About this protocol
Cite this protocol
Pérez-Severiano, F., Montes, S., Gerónimo-Olvera, C., Segovia, J. (2013). Study of Oxidative Damage and Antioxidant Systems in Two Huntington’s Disease Rodent Models. In: Kohwi, Y., McMurray, C. (eds) Trinucleotide Repeat Protocols. Methods in Molecular Biology, vol 1010. Humana Press, Totowa, NJ. https://doi.org/10.1007/978-1-62703-411-1_12
Download citation
DOI: https://doi.org/10.1007/978-1-62703-411-1_12
Published:
Publisher Name: Humana Press, Totowa, NJ
Print ISBN: 978-1-62703-410-4
Online ISBN: 978-1-62703-411-1
eBook Packages: Springer Protocols